Search research articles
Contact Us
Filters
Showing results (501-510 of 583) with videos related to
Page
of 59
Sort By:
Genome Research
|
March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia
Brian Giacopelli, Min Wang, Ada Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Haematologica
|
May 6, 2017
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, et al.
Leukemia
|
December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Susan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood
|
November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu Estey, David Grimwade, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Page
of 59
Search research articles
Search
Showing results (501-510 of 583) with videos related to
Sort By:
Page
of 59
Genome Research
|
March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia
Brian Giacopelli, Min Wang, Ada Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Haematologica
|
May 6, 2017
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
Dimitrios Papaioannou, Deedra Nicolet, Stefano Volinia, et al.
Leukemia
|
December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Susan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood
|
November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu Estey, David Grimwade, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Page
of 59